An intensive course in the Lee Silverman Voice Treatment, known as LSVT Loud, may be the best strategy to help people with Parkinson’s disease overcome speech and language problems, according to a trial from the University of Birmingham in the U.K. LSVT Loud, a program of vocal exercises developed…
Once-daily treatment with IRX4204, an oral small molecule being developed by Io Therapeutics, showed a potential to safely ease motor symptoms for most adults with early Parkinson’s disease taking part in a small, 30-day study. Building on this open-label Phase 1 clinical trial (NCT02438215), the company…
The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12…
Combining gait training with virtual reality and gamification elements — when game-like features are added to non-game activities — may help people with Parkinson’s disease see rehabilitation as a positive experience, a study suggests. That, in turn, could ultimately lead to better motor outcomes for patients, according to researchers.
People with a genetic predisposition to Parkinson’s disease are more likely to have early-onset symptoms, but lifestyle factors such as coffee consumption and tobacco and aspirin use may exert a more significant impact on that risk than common genetic risks, research findings suggest. While still exploratory, “our findings underline…
Two proteins, Aplp1 and Lag3, pair to allow toxic aggregates of alpha-synuclein — a hallmark of Parkinson’s disease — into nerve cells and help it spread across the brain, according to a study in mice. “Now that we know how Aplp1 and Lag3 interact, we have a new way…
People with Parkinson’s disease who don’t always take Nourianz (istradefylline) as prescribed are more likely to have fewer prescriptions for other approved medications and to have anxiety, mood changes, or cognitive problems, a study finds. Understanding how well patients follow the instructions for taking Nourianz, such as how…
Synthetic biology company Bit.bio introduced ioAstrocytes, a stem cell-derived version of astrocytes, cells that are known to play a significant role in Parkinson’s disease. Dysfunction of the star-shaped cells in the central nervous system (CNS, consisting of the brain and spinal cord) has been linked to the development…
A Phase 2 clinical study of AB-1005 (AAV2-GDNF), an experimental gene therapy AskBio is developing for Parkinson’s disease, is recruiting patients who are experiencing motor fluctuations despite being on a stable medication regimen for at least a month. Called REGENERATE-PD (NCT06285643), the study aims to enroll 87…
Coya Therapeutics is building upon its collaboration with the Houston Methodist Research Institute, in Texas, to advance research into exosomes, or tiny packets released from regulatory T-cells (Tregs), a type of immune cells that keep inflammation in check. These exosomes contain molecules that, similar to Tregs, can cross the…
Get regular updates to your inbox.